Epigenetic modulation reveals differentiation state specificity of oncogene addiction

• Published in: Nature communications 2021-03, Vol.12 (1), p.1536-15, Article 1536
• Main Authors: Khaliq, Mehwish, Manikkam, Mohan, Martinez, Elisabeth D., Fallahi-Sichani, Mohammad
• Format: Article
• Language: English
• Subjects: 13; 13/109; 13/89; 13/95; 14; 14/1; 14/56; 14/63; 49; 631/154/1435/2417; 631/553/2706; 631/67/1813/1634; 96/106; 96/98; Addictions; Animals; Anticancer properties; Cell differentiation; Cell Differentiation - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Differentiation (biology); Epigenesis, Genetic - drug effects; Epigenetics; Epigenomics - methods; Female; Heterogeneity; Histone Demethylases - metabolism; Histones; Humanities and Social Sciences; Humans; Inhibitors; Jumonji Domain-Containing Histone Demethylases - metabolism; Lysine; MAP kinase; MAP Kinase Signaling System - drug effects; Melanocytes; Melanocytes - metabolism; Melanoma; Melanoma - genetics; Melanoma - metabolism; Mice; Mice, Nude; multidisciplinary; Mutants; Mutation; Oncogene Addiction - genetics; Oncogenes; Pharmacology; Protein Kinase Inhibitors - pharmacology; Proteins; Proto-Oncogene Proteins B-raf - genetics; Regulators; Science; Science (multidisciplinary); Signal transduction; Signal Transduction - drug effects; Variability; Xenograft Model Antitumor Assays
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-021-21784-2

Hyperactivation of the MAPK signaling pathway motivates the clinical use of MAPK inhibitors for BRAF -mutant melanomas. Heterogeneity in differentiation state due to epigenetic plasticity, however, results in cell-to-cell variability in the state of MAPK dependency, diminishing the efficacy of MAPK inhibitors. To identify key regulators of such variability, we screen 276 epigenetic-modifying compounds, individually or combined with MAPK inhibitors, across genetically diverse and isogenic populations of melanoma cells. Following single-cell analysis and multivariate modeling, we identify three classes of epigenetic inhibitors that target distinct epigenetic states associated with either one of the lysine-specific histone demethylases Kdm1a or Kdm4b, or BET bromodomain proteins. While melanocytes remain insensitive, the anti-tumor efficacy of each inhibitor is predicted based on melanoma cells’ differentiation state and MAPK activity. Our systems pharmacology approach highlights a path toward identifying actionable epigenetic factors that extend the BRAF oncogene addiction paradigm on the basis of tumor cell differentiation state. Epigenetic mechanisms associated with the differentiation state of cancer cells and their heterogeneity influence tumor responses to oncogene-targeted therapies. In this study, the authors perform an epigenetic compound screen and single-cell analysis in BRAF -mutant melanoma cells to identify compounds that block three distinct drug-tolerant epigenetic states associated with either one of the lysine-specific histone demethylases Kdm1a or Kdm4b, or BET proteins.